Valbiotis Ships First Order to Chinese Joint Venture, Eyes 2026 China Launch

Valbiotis has announced the delivery of the first order to its Chinese joint venture, Hangzhou Valbiotis Life Health Technology. The initial delivery of ValbiotisPRO® products marks a significant step toward the company's planned commercial debut in China by late 2026. Comprising 50,000 units, the first shipment has already been dispatched, while the production of the second order is underway.

The company plans to market its products through leading cross-border e-commerce platforms at significantly higher retail prices than in France. Concurrently, registrations for three key products have been secured in Hong Kong and Singapore, with plans for both online and potential physical distribution in regional pharmacies.

These efforts align with Valbiotis's strategic aim to forge into Asia's markets by leveraging growing health needs prompted by increasing rates of cardiometabolic imbalances.